rs3825942 — LOXL1 G153D (Gly153Asp)

Missense variant in the elastin-crosslinking enzyme LOXL1; the common G allele is one of the strongest known genetic risk factors for exfoliation syndrome and exfoliation glaucoma, a leading cause of secondary glaucoma worldwide

See your personal result for LOXL1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

LOXL1 G153D — The Elastin Crosslinker at the Root of Exfoliation Glaucoma

Buried in the structure of every elastic tissue in your body — blood vessels, lungs, skin, eyes — is a protein called LOXL1 (Lysyl Oxidase-Like 1)11 LOXL1 (Lysyl Oxidase-Like 1)
an enzyme that catalyzes the crosslinking of tropoelastin monomers into mature elastin fibers, giving connective tissues their resilience and recoil. Without functional LOXL1, elastin fibers fail to assemble properly, accumulating as disorganized fibrillar material in tissues throughout the body. The rs3825942 variant — changing glycine to aspartate at position 153 of the LOXL1 protein — is one of the most powerful single-gene risk factors for any common eye disease ever identified: exfoliation syndrome (XFS)22 exfoliation syndrome (XFS)
a systemic disorder characterized by the abnormal production and accumulation of fibrillar extracellular matrix material in ocular and systemic tissues, and the secondary glaucoma it causes.

The Mechanism

LOXL1 is essential for the periocular elastin scaffold. In the trabecular meshwork and lens zonules — the structures governing aqueous humor drainage and lens support in the eye — LOXL1 crosslinks elastin to maintain normal tissue architecture. The Gly153Asp substitution alters the propeptide domain33 propeptide domain
the N-terminal proregion of LOXL1 that is cleaved during secretion; it regulates enzyme targeting and extracellular matrix deposition, disrupting LOXL1's ability to correctly position elastin crosslinks. The result is progressive accumulation of exfoliation material44 progressive accumulation of exfoliation material
a fibrillar aggregate of abnormally crosslinked elastin, fibrillin-1, and other matrix proteins that clogs the trabecular meshwork and impairs aqueous drainage, raising intraocular pressure and damaging the optic nerve.

The connection to cardiovascular health is not incidental. Exfoliation syndrome is now recognized as a systemic elastosis55 systemic elastosis
a body-wide disorder of elastic fiber metabolism, not merely an eye disease: exfoliation deposits have been identified in the heart, lungs, liver, kidneys, abdominal aorta, and cerebral arteries. Patients with exfoliation syndrome show [elevated plasma homocysteine | a marker of endothelial dysfunction and oxidative stress, and an independent cardiovascular risk factor], impaired conduit artery compliance, parasympathetic cardiovascular neuropathy, and increased rates of myocardial dysfunction and aortic aneurysm66 aortic aneurysm
abnormal widening of the aorta due to weakened elastic wall structure.

The Evidence

The landmark discovery came in 2007 when Thorleifsson et al. published in Science77 Thorleifsson et al. published in Science
Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007;317(5843):1397-1400 that rs3825942 and rs1048661 together explain almost all population-level susceptibility to exfoliation glaucoma. Individuals homozygous for the high-risk haplotype (GG at rs3825942) face over 100-fold elevated risk88 over 100-fold elevated risk
a population-attributable risk exceeding 99% in Icelandic cohorts — one of the highest effect sizes ever reported for a common genetic variant.

Replication was rapid and global. Hewitt et al. 200899 Hewitt et al. 2008
Ancestral LOXL1 variants associated with pseudoexfoliation in Caucasian Australians. Human Mol Genet 2008;17(5):710-6 confirmed that Caucasian Australians share the same GG risk haplotype with OR 7.20 (95% CI 3.04–20.75) versus non-carriers, though with 9-fold lower disease penetrance than Nordic populations — suggesting environmental or epistatic modifiers drive clinical expression. Yamamoto et al. 20081010 Yamamoto et al. 2008
Confirmed the GG genotype significantly associated with exfoliation glaucoma in Japanese patients (p=2.1×10⁻⁸) under a recessive model, though the rs1048661 variant shows a population-dependent risk allele reversal between European (G allele risk) and East Asian (T allele risk) populations.

An updated meta-analysis of 5,022 cases and 8,962 controls1111 updated meta-analysis of 5,022 cases and 8,962 controls
Li et al. 2021, PLoS One PMID 33909695 confirmed rs3825942 as a significant XFS/XFG risk factor across Caucasian, Asian, and African populations, though with pronounced variation in effect size by ancestry. The 2016 meta-analysis of 25 studies1212 2016 meta-analysis of 25 studies
Wang et al. J Glaucoma PMID 25304275 found that in Black South African populations, the AA genotype confers risk — a full reversal of the European allele-risk direction — underscoring that this variant's clinical interpretation must account for ancestry.

Practical Actions

For people of European ancestry with GG genotype, this represents a major risk factor for exfoliation glaucoma — the most common identifiable cause of secondary glaucoma worldwide. Since glaucoma is typically asymptomatic until significant optic nerve damage has occurred, proactive monitoring is the critical intervention. Annual dilated eye exams with intraocular pressure measurement1313 Annual dilated eye exams with intraocular pressure measurement
IOP elevation is the primary modifiable risk factor in glaucoma; early detection enables treatment before vision loss can identify exfoliation deposits, zonular laxity, and early optic nerve changes before functional vision loss.

Because XFS is a systemic condition, the cardiovascular implications warrant attention alongside the ophthalmologic ones. Holló 20181414 Holló 2018
Vascular Dysfunction in Exfoliation Syndrome, J Glaucoma documents conduit artery stiffness, parasympathetic dysfunction, and elevated homocysteine as systemic vascular features of the syndrome — risk factors that may benefit from targeted management.

Interactions

The rs3825942 G153D variant does not act alone. The adjacent rs1048661 variant (R141L, Arg141Leu) in the same exon of LOXL1 acts in concert with rs3825942 — the two variants form a haplotype, and carrying GG at both positions identifies the highest-risk individuals. A third variant, rs2165241 (intronic), also contributes to XFS risk in Europeans but not significantly in Asians. Together, these three variants tag the LOXL1 risk haplotype that accounts for nearly all population-attributable risk for exfoliation glaucoma in Europeans.

The systemic elastin connection also creates a potential interaction with genes governing fibrillin-1 (FBN1) and other extracellular matrix proteins — LOXL1 deposits co-localize with fibrillin-1 in exfoliation material, and both are essential for elastic fiber microfibril assembly. Variants in FBN1 (Marfan syndrome pathway) and related matrix genes may compound the connective tissue vulnerability conferred by rs3825942.

Genotype Interpretations

What each possible genotype means for this variant.

AA Protective Genotype Beneficial

Rare protective genotype — substantially reduced exfoliation syndrome risk

You carry two copies of the minor A allele at rs3825942, the protective genotype at this LOXL1 variant. Only about 2% of people of European ancestry share this genotype. Your LOXL1 protein carries aspartate at position 153 on both chromosomes, which is associated with a substantially reduced risk of developing exfoliation syndrome and exfoliation glaucoma compared to people with the common GG genotype. Note that while this specific variant is protective, exfoliation glaucoma can still arise from other genetic and environmental factors, and routine eye care remains important for overall eye health.

AG One Risk Allele Intermediate

One copy of the common risk allele — moderately elevated exfoliation syndrome risk

The G allele at rs3825942 encodes the common glycine form at position 153 of LOXL1. In European populations, this is the ancestral allele, carried by approximately 85% of individuals on at least one chromosome. Heterozygosity places you at elevated but intermediate risk — the largest GWAS studies indicate that AG carriers show a risk profile between the protective AA and high-risk GG genotypes, consistent with additive inheritance. The association is particularly strong in Nordic (Icelandic, Scandinavian) and Australian Caucasian populations, where LOXL1 accounts for >99% of population-attributable exfoliation glaucoma risk. Note that this variant should be interpreted together with rs1048661 (R141L), the adjacent LOXL1 exon 1 variant, for a complete LOXL1 haplotype risk assessment.

GG Homozygous Risk Allele High Risk

Two copies of the common risk allele — substantially elevated exfoliation glaucoma risk

The GG genotype means both copies of your LOXL1 protein carry glycine at position 153. This is the common ancestral form in European populations, but despite its frequency, it carries dramatically elevated exfoliation syndrome risk compared to the rare protective AA genotype. The Thorleifsson et al. Science 2007 discovery study found that the LOXL1 high-risk haplotype (which tags GG at rs3825942) confers a population-attributable risk exceeding 99% in Icelandic cohorts — meaning nearly all exfoliation glaucoma in that population is attributable to LOXL1 genotype. Penetrance varies substantially by geography: Nordic populations have dramatically higher XFS rates than Australian Caucasians carrying the same GG genotype (Hewitt 2008), indicating that additional environmental or genetic modifiers — UV exposure, latitude, LOXL1 expression regulators — modulate clinical disease expression.

Exfoliation glaucoma is the world's most common identifiable cause of secondary open-angle glaucoma. It tends to be more asymmetric, more rapidly progressive, and more difficult to control medically than primary open-angle glaucoma. Early detection during the presymptomatic exfoliation syndrome phase — before IOP rises and optic nerve damage begins — is the window for effective prevention.

Because LOXL1 is expressed in vascular smooth muscle and elastic tissues throughout the body, GG carriers also have modestly elevated risk of systemic vascular complications including conduit artery stiffness and reduced aortic root elasticity. Elevated homocysteine — a systemic marker in exfoliation syndrome — further compounds endothelial vulnerability.